🟢 ROIV is trading 8.3% up today after a GAAP earnings beat fueled by a $770.2 million Moderna settlement gain

ROIV is trading 8.3% up at $30.54 following its Q4 earnings release, which featured a significant GAAP EPS beat despite weaker-than-expected revenue.

• The earnings surprise was primarily driven by a $770.2 million one-time litigation gain resulting from a $2.25 billion settlement with Moderna.
• Management provided an upbeat pipeline update and reported a strengthened cash position of $4.3 billion, providing a clear catalyst for the stock to break out of its recent range.